Insulin Stimulates cAMP-response Element Binding Protein Activity in HepG2 and 3T3-L1 Cell Lines*

Dwight J. KlemmDagger §, William J. Roeslerpar , Tracy Boras**, Lillester A. ColtonDagger , Kimberly Felder**, and Jane E-B. Reusch**Dagger Dagger §§

From the Dagger  Department of Allergy and Clinical Immunology, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206, the ** Research Service, Veterans Affairs Medical Center, Denver, Colorado 80220, the § Departments of Biochemistry and Molecular Genetics and Dagger Dagger  Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80220, and the par  Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N-5E5

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Earlier studies from our laboratory demonstrated an insulin-mediated increase in cAMP-response element binding protein (CREB) phosphorylation. In this report, we show that insulin stimulates both CREB phosphorylation and transcriptional activation in HepG2 and 3T3-L1 cell lines, models of insulin-sensitive tissues. Insulin stimulated the phosphorylation of CREB at serine 133, the protein kinase A site, and mutation of serine 133 to alanine blocked the insulin effect.

Many of the signaling pathways known to be activated by insulin have been implicated in CREB phosphorylation and activation. The ability of insulin to induce CREB phosphorylation and activity was efficiently blocked by PD98059, a potent inhibitor of mitogen-activated protein kinase kinase (MEK1), but not significantly by rapamycin or wortmannin. Likewise, expression of dominant negative forms of Ras or Raf-1 completely blocked insulin-stimulated CREB transcriptional activity. Finally, we demonstrate an essential role for CREB in insulin activation of fatty-acid synthase and fatty acid binding protein (FABP) indicating the potential physiologic relevance of insulin regulation of CREB.

In summary, insulin regulates CREB transcriptional activity in insulin-sensitive tissues via the Raf right-arrow MEK pathway and has an impact on physiologically relevant genes in these cells.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Insulin binding to its cell surface receptor results in alterations in the expression of many genes for cellular growth, differentiation, and proliferation. Specific insulin responsive elements have been identified in the promoters of several genes (1-4). Peroxisome proliferator-activated receptors and other steroid hormone receptors have been implicated in regulating gene transcription through these insulin responsive elements (2, 4, 5). In other genes, insulin responsive sites have been mapped to regions containing cAMP responsive elements (CREs)1 and serum responsive elements (6-9). Consistent with these findings, many insulin-regulated genes are also regulated by extracellular stimuli that modulate intracellular cAMP levels (2, 10-17) (Table I). Previously, we demonstrated that phosphorylation of CREB was stimulated by insulin in primary rat adipocytes and HIRc cells (18, 19). This observation posed an important question regarding the impact of insulin-mediated CREB phosphorylation on CREB transactivation and the post-receptor pathways activated by insulin responsible for this effect.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Genes transcriptionally regulated by both insulin and cAMP

Cyclic AMP regulates the transcription of target genes primarily through the phosphorylation of the cAMP-response element binding protein (CREB) by protein kinase A (PKA) on serine 133 (of CREB-341 or serine 119 of CREB-327) of the CREB molecule (20-23). We demonstrated an analogous response to insulin and identified that this increase in phosphorylation was at least in part due to a decrease in nuclear protein phosphatase-2A activity. These experiments were the first to show a transient increase in CREB phosphorylation and regulation of a nuclear, serine/threonine-specific protein phosphatase in response to activation of a tyrosine kinase growth factor receptor. Simultaneously, Ginty et al. (24) described a similar increase in CREB phosphorylation in response to nerve growth factor (NGF), which binds to another tyrosine kinase growth factor receptor, in PC12 cells. It was stated in this paper that CREB phosphorylation alone by NGF was not sufficient to activate a Gal-4 CREB reporter. Since the time of these initial observations, an explosion of new data on growth factor, Ca2+, and cytokine regulation of CREB has emerged, and a number of post-receptor signaling pathways including ERK 1/2 pathway, pp70 S6 kinase pathway, p38 pathway, and PI-3 kinase pathway have been implicated in CREB regulation. The kinases responsible for serine 133 phosphorylation of CREB in addition to PKA have been in the rsk or MAP KAP kinase family, specifically RSK2, MAP KAP2, MAP KAP3, and MNK.

In this report, we demonstrate that insulin stimulates the phosphorylation of CREB at serine 133 and thereby enhances CREB transcriptional activity in the HepG2, human hepatoma cells, and in mouse 3T3-L1 fibroblasts and adipocytes. CREB phosphorylation and activation increased rapidly following the addition of physiological concentrations of insulin, but no change in CREB DNA binding activity was observed. Pharmacological inhibitors of PI-3 kinase or pp70 S6 kinase did not significantly inhibit insulin-stimulated CREB phosphorylation and activity. However, inhibition of the MAP kinase signaling pathway through the expression of a dominant negative Ras and Raf-1, or with the MAP kinase kinase (MEK) inhibitor, PD98059, blocked the effects of insulin on CREB. These studies indicate that the phosphorylation of CREB at serine 133 in response to insulin requires the MAP kinase pathway. Furthermore, we demonstrate that dominant negative CREB, K-CREB, will disrupt insulin activation of transcription from the promoters of the phosphoenolpyruvate carboxykinase (PEPCK), fatty-acid synthetase (FAS), and fatty acid binding protein (FABP) genes indicating a plausible physiologic role for CREB in adipocyte function.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Cell culture media and supplies were from Life Technologies, Inc. (Beverly, MA), Gemini Bioproducts (Gaithersburg, MD), and Specialty Media, Inc. (Lavallette, NJ). 3T3-L1 fibroblasts were provided by Dr. Ted Ciraldi (La Jolla, CA). Luciferase assay reagents were obtained from Analytical Luminescence Laboratory (San Diego, CA), and chloramphenicol acetyltransferase enzyme-linked immunosorbent assay kits were from Boehringer Mannheim. A plasmid containing an enhancerless thymidine kinase (TK) promoter linked to four copies of the Gal4 regulatory sequence driving expression of a luciferase reporter gene (pGal4TK-LUC) was provided by Dr. James Hoeffler (Invitrogen, San Diego, CA). Expression vectors for Gal4-CREB proteins with serine to alanine substitutions at amino acids 117, 129, and 133 in the CREB transactivation region linked to the Gal4 DNA binding domain (designated Gal4-CREB-341 S117A, S129A, and S133A, respectively) were generated as described elsewhere (25). An expression vector (pRSV-KCREB) for the dominant negative CREB inhibitor protein, KCREB, was provided by Dr. Richard Goodman (Oregon Health Sciences University, Portland, OR). Plasmids for the expression of constitutively active Ras (pSVRas), dominant negative Raf (pRSVC4BRaf) were supplied by Dr. Ulf Rapp (Strathlenkunde, Germany). [32P]orthophosphate was purchased from ICN (Irvine, CA). Okadaic acid was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). CREB- and P-CREB-specific antibodies were purchased from New England Biolabs (Beverly, MA). All other reagents were of molecular biology grade or better and were purchased from Sigma. Rapamycin and wortmannin were obtained from BioMol (Plymouth Meeting, PA), and PD98059 was a gift from Parke-Davis.

Cell Lines and Transfection Procedures-- HepG2, human hepatoma cells, were obtained from the American Type Culture Collection (Rockville, MD) and grown in low glucose Dulbecco's modified Eagle's medium (DMEM)/F12 containing 5% fetal calf serum (FCS), and 5% calf serum. 3T3-L1 fibroblasts were a gift of Ted Ceraldi (University of California, San Diego). 3T3-L1 fibroblasts were passaged in low glucose DMEM plus 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, and 450 ng/ml fungizone. 3T3-L1 fibroblasts were differentiated into adipocytes after reaching confluency by the addition of differentiation medium (high glucose DMEM containing 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, 500 µM isobutylmethylxanthine, 1 µM dexamethasone, and 1 µg/ml insulin). After 2 days, the 3T3-L1 cells were transferred to adipocyte growth medium (high glucose DMEM plus 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, and 1 µg/ml insulin) and refed every 2 days (26). Differentiation of fibroblasts to mature adipocytes was confirmed by Oil Red staining of lipid vesicles.

Plates of HepG2 and 3T3-L1 fibroblasts and adipocytes were grown to 70-80% confluency and transfected with the indicated plasmids by calcium phosphate-DNA coprecipitation as described by Wadzinski et al. (27) or using LipofectAMINE according to the manufacturer's directions (Life Technologies, Inc.). Cells were treated with insulin and/or other reagents at the concentrations and times specified in the figure legends. Luciferase assays were performed on a Monolight 2010 luminometer using the Enhanced Luciferase Assay kit (Analytical Luminescence Laboratory, San Diego, CA) according to the supplier's directions. Transfection efficiencies were normalized by cotransfecting the cells with a plasmid containing a chimeric SV40 promoter/beta -galactosidase gene, and beta -galactosidase levels were measured as described previously (27). All experiments were repeated at least three times, and consistent results were obtained in all cases.

Immunoprecipitation and Tryptic Phosphopeptide Mapping of 32P-CREB-- HepG2 and 3T3-L1 fibroblasts and adipocytes were grown to approximately 80% confluency as described above. Plates of cells (2.5 × 106/plate) were washed with phosphate-buffered saline, and the medium was replaced with 5 ml of phosphate-free DMEM containing 1% bovine serum albumin and 1 mCi of [32P]orthophosphate. The plates were incubated 4-16 h at 37 °C and then treated with insulin and/or other agents for the indicated times.

At each time point, the medium was removed from the cells, which were washed once with cold phosphate-buffered saline. The cell pellets were lysed in 1 ml of 20 mM Hepes, pH 7.9, containing 1% sodium dodecyl sulfate (SDS), and 0.1% 2-mercaptoethanol in a boiling water bath for 2 min. The lysates were diluted with 9 ml of 20 mM Hepes, pH 7.9, containing 1% Nonidet P-40, 1 mM EDTA, 1 µg/ml leupeptin, 1 mM benzamidine, 1 µg/ml pepstatin A, 50 mM beta -glycerol phosphate, 2 mM sodium vanadate, 50 mM sodium fluoride, 50 µM phenylarsine oxide, and 100 nM okadaic acid. After normalizing the supernatants for protein concentration, CREB was recovered from the supernatants by immunoprecipitation with CREB-specific antibodies covalently linked to protein A-Sepharose beads with dimethyl pimelimidate (27).

Immunoprecipitated material was resolved on 10% polyacrylamide-SDS gels. The identity of the CREB band and the relative amounts of CREB recovered at each time point were determined by Western blotting. Tryptic phosphopeptide mapping of phosphorylation sites within CREB was performed as described previously (28).

Western Blot Analysis of CREB and P-CREB-- Lysates from HepG2 cells and 3T3-L1 fibroblasts and adipocytes treated with insulin and/or other reagents were prepared as described above at the times indicated in the figure legends. After correcting for protein concentrations, the lysates were resolved on 10% polyacrylamide-SDS gels and transferred to nitrocellulose. The nitrocellulose blots were blocked with phosphate-buffered saline containing 5% dry milk and 0.1% Tween 20 and then treated with antibodies that recognize phosphorylated CREB (P-CREB) alone or that recognize both unphosphorylated and phosphorylated forms of CREB. The blots were washed and subsequently treated with goat anti-rabbit IgG conjugated to alkaline phosphatase. After the blots were washed, specific immune complexes were visualized with bromochloroindoyl phosphate and nitro blue tetrazolium.

In some experiments, proteins were transferred to PVDF membranes that were then blocked in 20 mM Tris-HCl, pH 7.9, 8.5% NaCl (TBS) containing 5% Blotting Grade Non-Fat Dry Milk and 0.1% Tween 20 for 1 h (Blocking Buffer). The blots were then incubated with the indicated primary antibodies in TBS containing 5% bovine serum albumin and 0.1% Tween 20. Membranes were then rinsed three times in Blocking Buffer and then twice in 10 mM Tris-HCl, pH 9.5, 10 mM NaCl, 1 mM MgCl2. Blots were then incubated with 1:500 dilution of CDP-Star reagent prepared in 1 × Assay Buffer (both reagents from New England Biolabs, Beverly, MA) for 5 min and then exposed to film.

Electrophoretic Mobility Shift Assay-- The binding affinities of unphosphorylated CREB and CREB phosphorylated in response to insulin were calculated from equilibrium binding data obtained from electrophoretic mobility shift assays performed with concentrations of 32P-labeled CREB probe from 0.1 to 20 ng per 20-µl reaction. The binding of CREB to 32P-labeled probe was saturable at high probe concentrations and was found to be reversible since the addition of unlabeled CRE probe to electrophoretic mobility shift assay reactions prior to electrophoresis decreased CREB DNA binding as compared with reactions with no unlabeled probe. Nuclear extract preparations, electrophoretic mobility shift assays, and Scatchard analysis of equilibrium binding data were performed as described previously (29, 30).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Insulin Stimulates Phosphorylation of CREB at Serine 133-- A number of laboratories have reported that the activation of certain tyrosine kinase/growth factor receptors, such as NGF receptor, epidermal growth factor receptor (24), and fibroblast growth factor receptor (4), increases the phosphorylation and transcriptional activity of the nuclear protein, CREB. In one of the first reports of this phenomenon, we demonstrated that insulin produced a transient increase in CREB phosphorylation in primary rat adipocytes (18). Our initial experiments also showed that insulin transiently decreased nuclear protein phosphatase 2A activity that could partly account for increased CREB phosphorylation (18, 19). However, the effect of insulin on CREB transcriptional activity was not addressed nor was the site(s) at which CREB was phosphorylated in response to insulin identified.

Insulin Stimulates CREB Phosphorylation at Serine 133 in a Time- and Dose-dependent Manner-- To assess further the impact of insulin on CREB phosphorylation, we used two cell lines representative of normal insulin-responsive tissues: HepG2 hepatoma cells derived from human liver and 3T3-L1 fibroblasts and adipocytes as representative of adipose tissue. As shown in Fig. 1A, both insulin and Bt2cAMP rapidly increased the level of 32P-labeled CREB in HepG2 cells (panel CREB IP). A significant increase in 32P-labeled CREB was noted after incubating the cells with insulin for only 20 min, and the levels continued to increase for at least 2 h. When the cells were treated with Bt2cAMP, maximal levels of CREB phosphorylation were observed after only 40 min. Similar results were obtained by Western blot analysis of nuclear extracts with antibodies that specifically recognize CREB phosphorylated at serine 133 (31) or (Fig. 1A, panel P-CREB Ab). These results indicated that at least one of the sites in the CREB protein molecule phosphorylated in response to insulin was the PKA recognition site. Total CREB protein levels did not change with either insulin or Bt2cAMP treatment as determined from Western blots using antibodies that recognize both unphosphorylated and phosphorylated forms of CREB (Fig. 1A, panel CREB Ab).


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 1.  

Insulin stimulates phosphorylation of CREB serine 133 in HepG2 cells and 3T3-L1 fibroblasts and adipocytes. A, HepG2 cells were grown in normal medium (P-CREB AB and CREB Ab) or in medium supplemented with 1 mCi/ml [32P]orthophosphate (CREB-IP). The cells were then treated with either 0.5 mM Bt2cAMP or 10 nM insulin for the times indicated above the figure. The 0 time (control) lane is on the far left. For cells grown in normal medium, cell lysates were prepared at each time point, and equal amounts of lysate protein were separated on 10% polyacrylamide-SDS gels and transferred to nitrocellulose. Separate blots were probed with antibodies specific for CREB phosphorylated at serine 133 (P-CREB Ab) or total CREB (CREB Ab). Equal amounts of lysate protein prepared from [32P]orthophosphate-labeled cells (CREB-IP) were immunoprecipitated with antibodies to total CREB. The immunoprecipitates were separated on 10% polyacrylamide-SDS gels that were exposed to film. The panel labeled CREB-IP shows a representative autoradiogram. The arrowheads indicate the positions of the P-CREB or CREB bands. B, 3T3-L1 fibroblasts, cultured overnight in serum-free medium, were treated with 100 nM insulin for the times shown above the figure. At each time point, the cells were lysed, and equal amounts of lysate protein were resolved on 12% polyacrylamide-SDS gels and transferred to PVDF membranes. Separate blots were probed with antibodies to serine 133-phosphorylated CREB (P-CREB Ab) or total CREB (CREB Ab). The positions of the P-CREB and CREB bands are indicated by arrowheads. C, 3T3-L1 fibroblasts cultured overnight in serum-free medium were treated with the indicated concentrations of insulin for 5 min or 0.5 mM Bt2cAMP for 60 min. Cells were lysed, and equal amounts of lysate protein were separated on 12% polyacrylamide-SDS gels and transferred to PVDF membranes. Individual blots were probed with P-CREB and total CREB antibodies as described above. D, 3T3-L1 fibroblasts and adipocytes were cultured overnight in serum-free medium containing 0.25 mCi/ml [32P]orthophosphate. The cells were treated with 100 nM insulin for the times shown and then lysed. Equal amounts of lysate protein were immunoprecipitated with antibodies to total CREB. The immunoprecipitates were resolved on SDS-polyacrylamide gels that were exposed to film. The panels show representative autoradiographs, and the arrowheads indicate the positions of the CREB bands. E, HepG2 cells were grown in medium containing 1 mCi/ml [32P]orthophosphate for 4 h. Untreated, control cells (NA) or cells treated with 10 nM insulin or 0.5 mM Bt2cAMP were lysed, and equal amounts of lysate protein were immunoprecipitated with antibodies to total CREB. The immunoprecipitates were resolved on SDS-polyacrylamide gels. The 32P-labeled CREB bands were identified from autoradiographs and excised from the gels. The CREB protein was eluted and digested with trypsin. Peptides were separated on cellulose thin layer plates by electrophoresis at pH 1.9 from left to right (anode on the right), followed by chromatography from bottom to top. The figure shows autoradiograms of the thin layer plates. The origin where the peptides were spotted is indicated by the dark spots. The maps labeled Insulin + Bt2cAMP and Insulin + PKA Peptide were generated by mixing tryptic phosphopeptides of CREB from insulin-treated cells with either phosphopeptides of CREB from Bt2cAMP-treated cells or with a 32P-labeled synthetic peptide (RPSYR) comprising the CREB PKA recognition sequence, respectively. The "PKA site" or serine 133-containing peptides are indicated with arrows.

Insulin also stimulated the phosphorylation of CREB at the PKA recognition site in 3T3-L1 fibroblasts, although the time course was more rapid than that observed in HepG2 cells (Fig. 1B, panel P-CREB Ab). In the 3T3-L1 fibroblasts, a significant increase in CREB phosphorylation was seen after only 5 min of insulin treatment and reached maximal levels at 30-60 min. We also examined the dependence of CREB phosphorylation on insulin concentration in the 3T3-L1 fibroblasts. Maximal phosphorylation of the CREB PKA site was observed in cells treated with 1.0 nM insulin (Fig. 1C, panel P-CREB Ab). Again, total CREB protein levels did not change (Fig. 1, B and C, panels CREB Ab). Fig. 1D shows that insulin stimulated 32P-CREB phosphorylation in both 3T3-L1 fibroblasts, as well as terminally differentiated adipocytes. Together, these data indicated that insulin stimulated CREB phosphorylation rapidly in cells representative of normal, insulin responsive tissues and at normal physiological concentrations.

Finally, the site(s) at which CREB was phosphorylated in response to insulin were determined by tryptic phosphopeptide mapping. No tryptic phosphopeptides were obtained from CREB isolated from untreated, control HepG2 cells (Fig. 1E, panel NA). However, a single phosphopeptide was obtained from CREB recovered from either insulin- or Bt2cAMP-treated cells (Fig. 1E, panels Insulin and Bt2cAMP). When tryptic phosphopeptides from either insulin- or Bt2cAMP-treated cells were mixed together and then subjected to two-dimensional mapping, a single major phosphopeptide was observed indicating that the phosphorylated peptides from the two sources comigrated (Fig. 1E, panel Insulin + Bt2cAMP). Likewise, a 32P-labeled, synthetic peptide comprising the CREB PKA-phosphorylation site (RPSYR, Ref. 27) also comigrated with the major CREB phosphopeptide from insulin-treated cells (Fig. 1E, panel Insulin + PKA Peptide). These mapping data and the ability of P-CREB (phosphoserine 133-specific) antibodies to bind to CREB from insulin-treated cells indicated that insulin stimulated the phosphorylation of CREB at serine 133, the PKA consensus site.

Insulin Stimulates CREB Transcriptional Activity-- Phosphorylation of CREB at serine 133 increases the transcriptional transactivation activity of the protein. To assess the ability of insulin to enhance CREB transcriptional activity, we measured the ability of insulin to regulate a luciferase reporter gene linked to the herpes simplex virus-thymidine kinase promoter containing four copies of the Gal4 response element (pGal4TK-LUC) in HepG2 cells and 3T3-L1 fibroblasts and adipocytes. The cells were cotransfected with an expression vector from which a chimeric protein containing the Gal4 DNA binding domain linked to the CREB transactivation region was expressed (pRSV-Gal4). Since mammalian cells lack transcription factors that bind the Gal4 consensus sequence, this system directly measures the effect of insulin on the CREB transactivation region of the chimeric protein. Control cells did not receive the Gal4-CREB expression plasmid. Transcription from the Gal4-responsive promoter was unaffected by insulin treatment in HepG2 cells in the absence of Gal4-CREB protein (Fig. 2A). However, when cotransfected with the Gal4-CREB-341 expression vector, insulin stimulated transcription from the Gal4 responsive promoter by 4.5-fold ± 0.27. Likewise, insulin stimulated Gal4-CREB responsive transcription 8.5-fold in 3T3-L1 fibroblasts and 4.45-fold in adipocytes.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 2.   Insulin stimulates CREB transcriptional activity in HepG2 cells and 3T3-L1 fibroblasts and adipocytes. A, HepG2 cells or 3T3-L1 fibroblasts or adipocytes were transfected with either pGal4TK-Luc alone or cotransfected with pGal4TK-Luc and pRSV-Gal4-CREB as indicated. The following day untreated, control cells (open bars) or cells treated with 10 nM insulin (HepG2) or 100 nM insulin (3T3-L1) for 4 h were lysed, and transcription levels (luciferase activity) were measured in the lysates. The figure shows data averaged from three to nine experiments. Levels of transcription are shown relative to levels measured in untreated cells cotransfected with the pRSV-Gal4-CREB plasmid. B, HepG2 cells were transfected with the plasmids pSV-Luc, pCRE-SV-Luc, or pDelta 71-Luc, and 3T3-L1 fibroblasts were transfected with the plasmids pPEPCK-Luc, pFAS-Luc, or pFABP-Luc as shown. As indicated, some cells were cotransfected with the plasmid, pRSV-KCREB. Each of these plasmids is described under "Experimental Procedures" and "Results." The following day, untreated control cells (open bars) or cells treated with insulin (cross-hatched bars) as described above were lysed. Luciferase activity in the lysates was measured as an index of transcriptional activity, and the data shown were averaged from three to nine experiments. Levels of transcription are shown relative to levels in untreated cells not transfected with pRSV-KCREB.

The effect of insulin on endogenous CREB protein in HepG2 cells was assessed by measuring transcription from an enhancerless SV40 promoter (pSV-luc) linked to three copies of a CRE consensus sequence (pCRESVluc) and a CREB-responsive/CRE-containing region of the somatostatin promoter (-71 to +53) (pDelta 71Luc). Transcription from both promoters was stimulated approximately 4-5-fold following treatment with 10 nM insulin for 4 h (Fig. 2B). However, no increase in transcription was noted from an enhancerless SV40 promoter lacking any CRE sequences. Likewise, no stimulation of transcription was noted when any of these reporter plasmids were cotransfected with an expression vector for the dominant negative CREB inhibitor protein, KCREB (5).

The ability of insulin to stimulate the transcriptional activity of the chimeric Gal4-CREB protein and the inhibition of insulin-stimulated transcription from CRE-containing promoters by the CREB-specific inhibitor, KCREB, clearly demonstrate that insulin enhances CREB transcriptional activity in cell lines representative of typical insulin-responsive tissues. To apply these observations to physiologically relevant genes in adipocytes, we examined three promoters as follows: the full-length PEPCK promoter, the fatty-acid synthase promoter (pFASluc), and the fatty acid binding protein promoter (pFABPluc) (courtesy of Steve Clarke, Austin, TX) fused to a luciferase reporter construct. Insulin led to a 4-5-fold induction of luciferase activity from the PEPCK and FAS promoter with a less profound, but statistically significant, increase in the FABP promoter activity (Fig. 2B). It is important to note that whereas PEPCK gene transcription is down-regulated by insulin in hepatocytes it is stimulated in adipocytes. We did not examine transcription from the PEPCK promoter in HepG2 cells in transient transfection studies because these experiments have been performed by other groups and the anticipated inhibition by insulin has not been observed (1). Additionally, the promoter regions responsible for insulin's inhibition of PEPCK gene transcription, as determined in stably transfected cell lines, does not map to the CRE of the PEPCK gene promoter (1, 7, 32). Importantly, cotransfection with dominant negative CREB disrupted the activation of all three promoters indicating a role of CREB in insulin regulation of these reporter constructs.

Parameters of Insulin-stimulated CREB Transactivation-- The ability of insulin to stimulate CREB transcriptional activity was further characterized in both HepG2 and 3T3-L1 fibroblasts using the Gal4-CREB system. Fig. 3 shows results obtained with HepG2 cells alone as similar results were observed in 3T3-L1 cells (not shown). When HepG2 cells were treated with 10 nM insulin, Gal4-CREB-mediated transcription increased linearly from 0 to 4 h of treatment (Fig. 3A). Transcription levels remained elevated for at least 8 h and then began to decline to basal levels (not shown). The time course for transcription did not match the time course for CREB phosphorylation shown in Fig. 1. However, similar differences have been reported for the time courses of transcription (luciferase expression) and CREB phosphorylation in response to cAMP analogs and appear to be due to the lag in overall luciferase expression as compared with the more rapid response of transcription alone. Gal4-CREB responsive transcription was also dependent on the concentration of insulin used to treat the cells (Fig. 3B). Transcription levels increased with insulin concentrations from 10-11 to 10-9 M. Concentrations of insulin higher than 10-9 M did not produce higher levels of transcription. Thus, the ability of insulin to enhance CREB transactivation occurs rapidly and at physiological concentrations of insulin.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Characterization of insulin-stimulated CREB transcriptional activity in HepG2 cells. A, HepG2 cells were cotransfected with pGal4TK-LUC and pRSV-Gal4-CREB-341. The following day the cells were treated with 10 nM insulin for the times indicated. Cells were lysed at each time point, and transcription levels (luciferase activity) were measured. Fold increases in transcription are relative to levels measured in untreated control cells at each time. B, HepG2 cells were transfected with the plasmids described above and treated the following day with the indicated concentrations of insulin for 4 h. Transcription (luciferase production) was measured in cell lysates, and the fold increases in transcription are relative to the level measured in untreated cells (no insulin). C, Scatchard analysis of nuclear protein binding to a CRE probe was performed with nuclear extracts from untreated HepG2 cells (open circle ) or from cells treated with 10 nM insulin for 5 min (square ) or 2 h (diamond ). Approximately 5 µg of protein from each of the nuclear extracts was incubated in binding reactions containing 32P-labeled CRE probe ranging from 0.01 to 20 ng. The reactions were separated on 6% non-denaturing polyacrylamide gels that were subsequently exposed to film. Levels of bound and free probe in each lane were determined by densitometry of the resulting autoradiograph. The data represent the average of three experiments.

Scatchard analysis of CREB DNA binding activity determined by gel retardation assay indicated that insulin had no effect on the ability of CREB to bind CRE sequences (Fig. 3C).

Insulin Stimulates CREB Transcriptional Activity through the Phosphorylation of Serine 133-- Our initial results demonstrated that insulin stimulated the phosphorylation of serine 133 of CREB. To confirm further the importance of serine 133 phosphorylation for CREB transcriptional activity, we next analyzed the ability of insulin to stimulate transcription from the Gal4-responsive promoter in the presence of wild type Gal4-CREB or Gal4-CREB proteins containing various mutations in the CREB transactivation domain (25). The wild type and mutant Gal4-CREB proteins were expressed at equivalent levels in these experiments as determined by Western blot analysis of cell lysates with Gal4-specific antibodies (data not shown). The data in Fig. 4 show that mutation of serine 133 to alanine completely blocks the ability of insulin to stimulate Gal4-CREB transcriptional activity in both HepG2 cells and 3T3-L1 fibroblasts. However, insulin was able to stimulate the transcriptional activity of other Gal4-CREB proteins having adjacent serines mutated to alanines (Gal4-CREBs S117A and S129A). Levels of basal transcription with these proteins was typically lower than observed with the wild type Gal4-CREB protein.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   CREB serine 133 is required for insulin-stimulated CREB transcriptional activity. 3T3-L1 fibroblasts were transfected with pGal4TK-LUC along with expression vectors for each of the wild type (WT) and mutant Gal4-CREB proteins indicated below the figure. The various Gal4-CREB plasmids and proteins are described under "Experimental Procedures" and "Results." Transfected HepG2 cells were cultured overnight in complete medium, whereas the 3T3-L1 cells were cultured in serum-free medium. The following day the cells were treated with either 10 nM (HepG2) or 100 nM (3T3-L1) insulin (cross-hatched bars). Untreated control cells and insulin-treated cells were lysed and luciferase activity measured as an index of transcriptional activity. Transcription levels are shown relative to levels measured in untreated HepG2 cells with no Gal4-CREB or untreated 3T3-L1 cells expressing wild type (WT) Gal4-CREB. The results were averaged for three to nine separate experiments. All constructs demonstrate statistically significant stimulation with insulin p < 0.05 except the pGal4CREB S133A and the Gal4CREB Delta 82.

Effect of Pharmacologic Inhibitors on CREB Phosphorylation and Activity-- Recent data indicate that multiple signal transduction pathways are capable of regulating CREB serine 133 phosphorylation (24, 33-39). Insulin-regulated pathways that have been implicated for serine 133 phosphorylation by other growth factors, cytokines, and cytosolic calcium include MAP kinases, pp70 S6 kinase (which requires PI-3 kinase for insulin regulation), and PKC. We examined the contribution of these pathways to the regulation of CREB phosphorylation and activity in 3T3-L1 fibroblasts using various pharmacological inhibitors. As shown in Fig. 5A, the insulin-induced phosphorylation of CREB serine 133 was unaffected by pretreatment with rapamycin, an inhibitor of pp70 S6 kinase, and minimally, but not significantly, affected by wortmannin, an inhibitor of PI-3 kinase. Preliminary experiments with the PKC inhibitor, bisindolylmaleimide, have also showed no change in insulin-stimulated CREB phosphorylation (not shown). However, PD98059, a potent and specific inhibitor of MAP kinase kinase 1 (MEK 1), completely blocked the insulin-mediated increase in CREB phosphorylation. No change in total CREB content was observed with any of the inhibitors (not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of MEK-1, but not pp70 S6 kinase or PI3 kinase, blocks insulin-stimulated CREB phosphorylation and transcriptional activity. A, untreated 3T3-L1 fibroblasts (None) or fibroblasts treated with 1 ng/ml rapamycin or 100 nM wortmannin for 30 min or 30 nM PD98059 for 60 min were subsequently incubated with (+) or without (-) 100 nM insulin for 5 min. Lysates from the cells were resolved on a 12% polyacrylamide-SDS gel and transferred to PVDF membranes that were probed with antibody specific for CREB phosphorylated at serine 133 (P-CREB Ab). The positions of the two phosphorylated CREB bands are indicated by the arrows. A representative autoradiogram is shown with the densitometric analysis of 9-17 such experiments summarized below. B, 3T3-L1 fibroblasts were cotransfected with pGal4TK-LUC and pRSV-Gal4-CREB-341 and cultured overnight in serum-free medium. Untreated 3T3-L1 fibroblasts (control) or cells pretreated with rapamycin, wortmannin, or PD98059 as described above were subsequently incubated without (open bars) or with 100 nM insulin (cross-hatched bars) or with 0.5 mM Bt2cAMP (solid bars) for 4 h. Luciferase activity was measured in the cell lysates as an index of transcriptional activity. Levels of transcription are shown relative to levels measured in cells not treated with insulin or any inhibitor. The data shown are averages from four to eight experiments.

To correlate these observations with transcriptional activity, we measured the effect of these agents on the Gal4-CREB-responsive transcription system. In these experiments, PD98059 completely inhibited insulin-stimulated transcription from the Gal4-CREB-responsive promoter (Fig. 5B). Rapamycin and wortmannin did not inhibit insulin-stimulated/Gal4-CREB-mediated transcription, although the magnitude of the transcriptional responses with wortmannin was less than seen in controls. These data strongly suggested that insulin regulated CREB activity through the MAP kinase signaling pathway.

Effect of Constitutively Active and Dominant Negative Ras and Raf on Insulin-stimulated CREB Transcriptional Activity-- To confirm the previous observations implicating the MAP kinase pathway in insulin-stimulated CREB regulation, we measured the effect of insulin on transcription from the Gal4-responsive promoter in the presence of Gal4-CREB in 3T3-L1 fibroblasts cotransfected with plasmids for the expression of constitutively active Ras or Raf-1 (pSVRas and pRSVBXBRaf, respectively) or dominant negative Ras or Raf-1 (pZCRN17Ras and pRSVC4BRaf, respectively). In these experiments, insulin stimulated CREB-dependent transcription in control cells by 4.1 (Fig. 6). The expression of either constitutively active Ras or Raf significantly increased basal levels of transcription from the Gal-4-responsive promoter, but no additional stimulation with insulin was observed. The dominant negative forms of Ras and Raf did not affect basal levels of transcription but efficiently blocked the ability of insulin to stimulate CREB transcriptional activity. The inability of insulin to stimulate further CREB activity in cells expressing constitutively active Ras or Raf proteins and the ability of negative Ras and Raf to inhibit insulin-stimulated CREB activity support the contribution of the Ras-Raf-MEK1-MAP kinase pathway to insulin regulation of CREB transcriptional activity.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of constitutively active Ras or Raf or dominant negative Ras or Raf on insulin-stimulated CREB transcriptional activity. 3T3-L1 fibroblasts were cotransfected with pGal4TK-LUC and pRSV-Gal4-CREB-341. As indicated below the figure, the cells were also cotransfected with expression vectors for constitutively active Ras (+Ras) or Raf (+Raf), or dominant negative Ras (-Ras) or Raf (-Raf). Control cells (Cntrl) did not receive additional plasmids. After overnight incubation in serum-free medium, untreated cells (open bars) or cells treated with 100 nM insulin (cross-hatched bars) were lysed, and luciferase activity was measured in the lysates as an index of transcriptional activity. The data are averages from three experiments and are shown relative to levels measured in untreated, control cells.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Insulin is primarily a metabolic hormone that also regulates the proliferation and differentiation of a number of cells and tissues. One of the mechanisms by which insulin regulates transcription is through the phosphorylation and transcriptional activation of CREB in Rat-1A cells, hepatoma cells, preadipocyte, and adipocyte cell lines. Since our initial observations that insulin enhanced CREB phosphorylation in primary adipocytes and HIRc cell lines (18, 19), a number of groups have seen a similar response to other growth factors including NGF and fibroblast growth factor, via the ERK1/2 and p38 MAPK pathways (4, 24, 39). For these growth factors, both studied in neuronal cell lines, Rsk2 and MAPKAP2, rsk family kinases have been implicated in CREB regulation (4, 39). Additionally, PKC, elevated intracellular Ca2+, and IgG (via pp70 S6 kinase) can phosphorylate CREB on serine 133. Whether these phosphorylations lead to CREB transactivation appears to depend on cell type and whether the cells are exposed to other factors, such as cAMP agonists simultaneously (40). The importance of the work presented in this paper is the observation that in cell line models of classic, insulin-sensitive tissues, hepatocytes and adipocytes, insulin regulates this ubiquitous transcription factor that has been demonstrated to have a pivotal role in cellular differentiation (24, 40, 41).2

We initially observed that insulin led to CREB phosphorylation in primary adipocytes. This was an unexpected finding since insulin's actions classically oppose cAMP which, at that time, was felt to be the primary regulating agent for CREB (21-23, 31). Subsequently, we demonstrated that this enhanced CREB phosphorylation occurred in Rat-1A fibroblasts overexpressing normal human insulin receptors (HIRc cells) (18). The relevance of these observations to CREB transcriptional activity was assessed using multiple promoter constructs including the somatostatin CRE reporter and a truncated PEPCK CRE reporter, each of which would be regulated by endogenous CREB and other CRE binding transcription factors. Also, to assess CREB specifically and exclude other CRE binding transcription factors, the Gal4TKLUC reporter system, a Gal4-CREB responsive transcription system was employed. In this system, either insulin or Bt2cAMP stimulated transcription to a similar extent in HIRc cells. Thus, insulin-mediated CREB phosphorylation appeared to be transcriptionally relevant.

CREB was initially characterized as a substrate of PKA. Activation of PKA by increases in intracellular cAMP results in the increase of CREB transcriptional transactivation activity through the phosphorylation of CREB serine 133 (22, 31). We have shown here that the treatment of hepatoma, fibroblast, and adipocyte cells with insulin also results in the phosphorylation of CREB at serine 133. The importance of CREB serine 133 phosphorylation following insulin treatment was further highlighted by experiments in which mutation of serine 133 to alanine completely blocked the insulin responsiveness of a chimeric Gal4-CREB protein in transfection assays. Mutation of other individual CREB serine residues to alanines had no significant effect on insulin responsiveness. These observations were consistent with data from other groups regarding the commonality of serine 133 for CREB transcriptional regulation by cAMP, NGF, fibroblast growth factor, and calcium (21-24, 31, 37, 39, 42).

Interestingly, although insulin or Bt2cAMP alone stimulates CREB activity, the simultaneous addition of both agents produced only a minimal increase in CREB transcriptional activity in HepG2 and 3T3-L1 fibroblasts, rather than an additive or synergistic stimulation.3 This is consistent with the observations from other groups (33) wherein cAMP stimulation led to a refractory period for subsequent activation. This effect was thought to be mediated by a non-kinase-dependent binding of RSK kinase to CREB binding protein (CBP) and a subsequent disruption of CREB-CBP-induced transcription (40). Our data support the hypothesis that multiple signaling pathways leading to CREB phosphorylation and transcriptional activation may not be synergistic.

Deciphering the pathway activated by insulin responsible for CREB phosphorylation and activation is important because the multiple post-receptor pathways activated by insulin presented a number of possibilities. The data presented in this paper strongly support the role of Ras right-arrow Raf-1 right-arrow MEK right-arrow ERK1/2 kinase pathway which is analogous to the observations of Ginty et al. (24) with NGF. The relevance of CREB regulation by insulin is highlighted by our demonstrating that activation of transcription from the PEPCK, FAS, and FABP gene promoters is blocked by dominant negative CREB in adipocytes. It will be interesting to define the phenotypic consequences of this novel mechanism of insulin-modulated gene expression.

    ACKNOWLEDGEMENTS

We acknowledge Elizabeth Millard for technical assistance. We thank Boris Draznin for support and thoughtful review of the manuscript. We appreciate the excellent secretarial support of Gloria Smith.

    FOOTNOTES

* This research was supported by National Institutes of Health Grants GM47117 (to D. J. K.) and DK02351, Veterans Administration Merit and Career Development Awards (to J. E-B. R.), and a Canadian Diabetes Association grant (to W. J. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Both authors contributed equally to this work.

§§ To whom correspondence should be addressed: Section of Endocrinology (111H), Veterans Affairs Medical Center, 1055 Clermont St., Denver, CO 80220. Tel.: 303-399-8020 (ext. 2775); Fax: 303-393-5271; E-mail: jreusch{at}sembilan.uchsc.edu.

1 The abbreviations used are: CRE, cAMP responsive elements; CREB, cAMP-response element binding protein; MAP, mitogen-activated protein; MEK, MAP kinase kinase; FAS, fatty-acid synthetase; FABP, fatty acid binding protein; NGF, nerve growth factor; PKA, protein kinase A; PEPCK, phosphoenolpyruvate carboxykinase; TK, thymidine kinase; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; Bt2cAMP, dibutyryl cyclic AMP; PVDF, polyvinylidene difluoride; Ab, antibody; KAP, kinase-activated protein.

2 D. J. Klemm, unpublished data.

3 J. E.-B. Reusch and D. J. Klemm, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Forest, C. D., O'Brien, R. M., Lucas, P. C., Magnuson, M. A., Granner, D. K. (1990) Mol. Endocrinol. 4, 1302-1310[Abstract]
  2. Moustaïd, N., Beyer, R. S., and Sul, H. S. (1994) J. Biol. Chem. 269, 5629-5634[Abstract/Free Full Text]
  3. Short, M. K., Clouthier, D. E., Schaefer, I. M., Hammer, R. E., Magnuson, M. A., Beale, E. G. (1992) Mol. Cell. Biol. 12, 1007-1020[Abstract]
  4. Tan, Y., Rouse, J., Zhang, A., Cariati, S., Cohen, P., and Comb, M. J. (1996) EMBO J. 15, 4629-4642[Abstract]
  5. Walton, K. M., Rehfuss, R. P., Chrivia, J. C., Lochner, J. E., Goodman, R. H. (1992) Mol. Endocrinol. 6, 647-655[Abstract]
  6. Bergot, M.-O., Diaz-Guerra, M.-J. M., Puzenat, N., Raymondjean, M., Kahn, A. (1992) Nucleic Acids Res. 20, 1871-1878[Abstract]
  7. O'Brien, R. M., Lucas, P. C., Yamasaki, T., Noisin, E. L., Granner, D. K. (1994) J. Biol. Chem. 269, 30419-30428[Abstract/Free Full Text]
  8. Quinn, P. G. (1994) J. Biol. Chem. 269, 14375-14378[Abstract/Free Full Text]
  9. Stumpo, D. J., Stewart, T. N., Gilman, M. Z., Blackshear, P. J. (1988) J. Biol. Chem. 263, 1611-1614[Abstract/Free Full Text]
  10. Aggerbeck, M., Garlatti, M., Feilleux-Duché, S., Veyssier, C., Daheshia, M., Hanoune, J., and Barouki, R. (1993) Biochemistry 32, 9065-9072[Medline] [Order article via Infotrieve]
  11. Cifuentes, M. E., Espinet, C., Lange, A. J., Pilkis, S. J., Hod, Y. (1991) J. Biol. Chem. 266, 1557-1563[Abstract/Free Full Text]
  12. el-Maghrabi, M. R., Lange, A. J., Kummel, L., and Pilkis, S. J. (1991) J. Biol. Chem. 266, 2115-2120[Abstract/Free Full Text]
  13. Granner, D., and Pilkis, S. (1990) J. Biol. Chem. 265, 10173-10176[Free Full Text]
  14. Iynedjian, P. B., Jotterand, D., Nouspikel, T., Asfari, M., and Pilot, P.-R. (1989) J. Biol. Chem. 264, 21824-21829[Abstract/Free Full Text]
  15. Jerkins, A. A., Liu, W. R., Lee, S., and Sul, H. S. (1995) J. Biol. Chem. 270, 1416-1421[Abstract/Free Full Text]
  16. Park, K., and Kim, K.-H. (1991) J. Biol. Chem. 266, 12249-12256[Abstract/Free Full Text]
  17. Suwanickul, A., Morris, S. L., and Powell, D. R. (1993) J. Biol. Chem. 268, 17063-17068[Abstract/Free Full Text]
  18. Reusch, J. E.-B., Hsieh, P., Klemm, D., Hoeffler, J., and Draznin, B. (1994) Endocrinology 135, 2418-2422[Abstract]
  19. Reusch, J. E.-B., Hsieh, P., Bhuripanyo, P., Carel, K., Leitner, J. W., Olefsky, J. M., Draznin, B. (1995) Endocrinology 136, 2464-2469[Abstract]
  20. Gonzalez, G. A., Yamamoto, K. K., Fischer, W. H., Karr, D., Menzel, P., Biggs, W., III, Vale, W. W., Montminy, M. R. (1989) Nature 337, 749-752[CrossRef][Medline] [Order article via Infotrieve]
  21. Lamph, W. W., Dwarki, V. J., Ofir, R., Montminy, M., and Verma, I. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4320-4324[Abstract]
  22. Lee, C. Q., Yun, Y., Hoeffler, J. P., Habener, J. F. (1990) EMBO J. 9, 4455-4465[Abstract]
  23. Yamamoto, K. K., Gonzalez, G. A., Biggs, W. H., III, Montminy, M. R. (1988) Nature 334, 494-498[CrossRef][Medline] [Order article via Infotrieve]
  24. Ginty, D. D., Bonni, A., and Greenberg, M. E. (1994) Cell 77, 713-725[Medline] [Order article via Infotrieve]
  25. Roesler, W. J., Graham, J. G., Kolen, R., Klemm, D. J., McFie, P. J. (1995) J. Biol. Chem. 270, 8225-8232[Abstract/Free Full Text]
  26. DePaolo, D., Reusch, J. E.-B., Carel, K., Bhuripanyo, P., Leitner, J. W., Draznin, B. (1996) Mol. Cell. Biol. 16, 1450-1457[Abstract]
  27. Wadzinski, B. E., Wheat, W. H., Jaspers, S., Peruski, L. F., Jr., Lickteig, R. L., Johnson, G. L., Klemm, D. J. (1993) Mol. Cell. Biol. 13, 2822-2834[Abstract]
  28. Kazlauskas, A., and Cooper, J. A. (1989) Cell 58, 1121-1133[Medline] [Order article via Infotrieve]
  29. Bokar, J. A., Roesler, W. J., Vandenbark, G. R., Kaetzel, D. M., Hanson, R. W., Nilson, J. H. (1988) J. Biol. Chem. 263, 19740-19747[Abstract/Free Full Text]
  30. Park, E. A., Gurney, A. L., Nizielski, S. E., Hakimi, P., Cao, Z., Moorman, A., Hanson, R. W. (1993) J. Biol. Chem. 268, 613-619[Abstract/Free Full Text]
  31. Gonzalez, G. A., and Montminy, M. R. (1989) Cell 59, 675-680[Medline] [Order article via Infotrieve]
  32. O'Brien, R. M., Lucas, P. C., Forest, C. D., Magnuson, M. A., Granner, D. K. (1990) Science 249, 533-537[Medline] [Order article via Infotrieve]
  33. Armstrong, R., Wen, W., Meinkoth, J., Taylor, S., and Montminy, M. (1995) Mol. Cell. Biol. 15, 1826-1832[Abstract]
  34. Enslen, H., Tokumitsu, H., and Soderling, T. R. (1995) Biochem. Biophys. Res. Commun. 207, 1038-1043[CrossRef][Medline] [Order article via Infotrieve]
  35. Sheng, M., and Greenberg, M. E. (1990) Neuron 4, 477-485[Medline] [Order article via Infotrieve]
  36. Sheng, M., McFadden, G., and Greenberg, M. E. (1990) Neuron 4, 571-582[Medline] [Order article via Infotrieve]
  37. Sheng, M., Thompson, M. A., and Greenberg, M. E. (1991) Science 252, 1427-1430[Medline] [Order article via Infotrieve]
  38. Xie, H., and Rothstein, T. L. (1995) J. Immunol. 154, 1717-1723[Abstract/Free Full Text]
  39. Xing, J., Ginty, D. D., and Greenberg, M. E. (1996) Science 273, 959-963[Abstract]
  40. Nakajima, T., Fukamizu, A., Takahashi, J., Gage, F. H., Fisher, T., Blenis, J., Montminy, M. R. (1996) Cell 86, 465-474[Medline] [Order article via Infotrieve]
  41. Heasley, L. E., Benedict, S., Gleavy, J., and Johnson, G. L. (1991) Cell Regul. 2, 479-489[Medline] [Order article via Infotrieve]
  42. Houglum, K., Lee, K. S., and Chojkier, M. (1997) J. Clin. Invest. 99, 1322-1328[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.